BR112022009716A2 - Dosagem de um inibidor de tirosina quinase de bruton - Google Patents
Dosagem de um inibidor de tirosina quinase de brutonInfo
- Publication number
- BR112022009716A2 BR112022009716A2 BR112022009716A BR112022009716A BR112022009716A2 BR 112022009716 A2 BR112022009716 A2 BR 112022009716A2 BR 112022009716 A BR112022009716 A BR 112022009716A BR 112022009716 A BR112022009716 A BR 112022009716A BR 112022009716 A2 BR112022009716 A2 BR 112022009716A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage
- tyrosine kinase
- kinase inhibitor
- bruton tyrosine
- bruton
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944674P | 2019-12-06 | 2019-12-06 | |
| US202063077996P | 2020-09-14 | 2020-09-14 | |
| US202063109698P | 2020-11-04 | 2020-11-04 | |
| PCT/US2020/063089 WO2021113497A1 (en) | 2019-12-06 | 2020-12-03 | Dosing of a bruton's tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009716A2 true BR112022009716A2 (pt) | 2022-08-09 |
Family
ID=73854977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009716A BR112022009716A2 (pt) | 2019-12-06 | 2020-12-03 | Dosagem de um inibidor de tirosina quinase de bruton |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12551463B2 (https=) |
| EP (1) | EP4069219A1 (https=) |
| JP (3) | JP7142173B2 (https=) |
| KR (2) | KR20230127372A (https=) |
| CN (1) | CN115175677A (https=) |
| AU (2) | AU2020397034B2 (https=) |
| BR (1) | BR112022009716A2 (https=) |
| IL (1) | IL292882A (https=) |
| MX (1) | MX2022006631A (https=) |
| WO (1) | WO2021113497A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| JP7142173B2 (ja) * | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101668574B1 (ko) | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN114716381B (zh) | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US10829488B2 (en) | 2016-08-05 | 2020-11-10 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| EP3612531B1 (en) | 2017-04-18 | 2022-08-24 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| KR20200108301A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| SG11202009933WA (en) | 2018-04-29 | 2020-11-27 | Beigene Ltd | Bcl-2 INHIBITORS |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| JP7142173B2 (ja) * | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
-
2020
- 2020-12-03 JP JP2021557408A patent/JP7142173B2/ja active Active
- 2020-12-03 IL IL292882A patent/IL292882A/en unknown
- 2020-12-03 KR KR1020237028538A patent/KR20230127372A/ko active Pending
- 2020-12-03 KR KR1020227022407A patent/KR20220100992A/ko not_active Ceased
- 2020-12-03 AU AU2020397034A patent/AU2020397034B2/en active Active
- 2020-12-03 US US17/782,758 patent/US12551463B2/en active Active
- 2020-12-03 CN CN202080095816.0A patent/CN115175677A/zh active Pending
- 2020-12-03 EP EP20825385.6A patent/EP4069219A1/en active Pending
- 2020-12-03 WO PCT/US2020/063089 patent/WO2021113497A1/en not_active Ceased
- 2020-12-03 MX MX2022006631A patent/MX2022006631A/es unknown
- 2020-12-03 BR BR112022009716A patent/BR112022009716A2/pt unknown
-
2022
- 2022-09-12 JP JP2022144243A patent/JP7654604B2/ja active Active
-
2024
- 2024-02-26 AU AU2024201263A patent/AU2024201263B2/en active Active
-
2025
- 2025-03-19 JP JP2025044178A patent/JP2025098099A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020397034A1 (en) | 2022-07-21 |
| AU2024201263A1 (en) | 2024-03-14 |
| AU2020397034B2 (en) | 2023-12-07 |
| JP2022518974A (ja) | 2022-03-17 |
| IL292882A (en) | 2022-07-01 |
| WO2021113497A1 (en) | 2021-06-10 |
| JP7654604B2 (ja) | 2025-04-01 |
| KR20220100992A (ko) | 2022-07-18 |
| EP4069219A1 (en) | 2022-10-12 |
| JP2022177119A (ja) | 2022-11-30 |
| US12551463B2 (en) | 2026-02-17 |
| NZ788615A (en) | 2024-10-25 |
| JP7142173B2 (ja) | 2022-09-26 |
| JP2025098099A (ja) | 2025-07-01 |
| KR20230127372A (ko) | 2023-08-31 |
| MX2022006631A (es) | 2022-09-07 |
| CA3160417A1 (en) | 2021-06-10 |
| US20230041515A1 (en) | 2023-02-09 |
| AU2024201263B2 (en) | 2025-05-01 |
| CN115175677A (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ777871A (en) | Small molecule modulators of il-17 | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| BR112016008016B8 (pt) | Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos | |
| PH12019500025A1 (en) | Cancer treatment combinations | |
| EA201992329A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201992334A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| EA201992784A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112021026369A2 (pt) | Derivados de 2h-indazol e seu uso no tratamento de doenças | |
| BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
| BR112021021826A8 (pt) | Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4 | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |